{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:08:07Z","timestamp":1790777287081,"version":"4.1.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.purol.2022.09.009","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T21:56:25Z","timestamp":1668549385000},"page":"1066-1101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"T.","family":"Murez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Branger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-H.","family":"Savoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Camparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Neuville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Van Hove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2022.09.009_bib0570","series-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018 - Volume 1\u00a0: Tumeurs solides [Internet]","first-page":"372","author":"Defossez","year":"2019"},{"issue":"5","key":"10.1016\/j.purol.2022.09.009_bib0575","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/andr.12515","article-title":"Trends in rates of inpatients treated for testicular cancer in France, 2000-2014","volume":"6","author":"Kudjawu","year":"2018","journal-title":"Andrology"},{"key":"10.1016\/j.purol.2022.09.009_bib0580","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canep.2018.12.011","article-title":"The rising incidence of testicular cancer among young men in Canada, data from","volume":"58","author":"Brenner","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.purol.2022.09.009_bib0585","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.euo.2020.06.011","article-title":"Temporal trends in the incidence of testicular cancer in the united states over the past four decades","volume":"4","author":"Reese","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib0590","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ejca.2013.11.035","article-title":"Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data","volume":"50","author":"Le Cornet","year":"2014","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"Suppl 2","key":"10.1016\/j.purol.2022.09.009_bib0595","first-page":"S57","article-title":"[Incidence and mortality of urological cancers in 2012 in France]","volume":"23","author":"R\u00e9billard","year":"2013","journal-title":"Progres En Urol J Assoc Francaise Urol Soc Francaise Urol"},{"issue":"9 Pt B","key":"10.1016\/j.purol.2022.09.009_bib0600","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1464-410X.2009.08854.x","article-title":"Epidemiology of testicular cancer","volume":"104","author":"Manecksha","year":"2009","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.purol.2022.09.009_bib0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.03.013","article-title":"Incident testicular cancer in relation to using marijuana and smoking tobacco: a systematic review and meta-analysis of epidemiologic studies","volume":"38","author":"Song","year":"2020","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib0610","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00330-014-3437-x","article-title":"Testicular microlithiasis imaging and follow-up: guidelines of the ESUR scrotal imaging subcommittee","volume":"25","author":"Richenberg","year":"2015","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.purol.2022.09.009_bib0615","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/iju.12441","article-title":"Clinical characteristics and oncological outcomes of testicular cancer patients registered in 2005 and 2008: the first large-scale study from the Cancer Registration Committee of the Japanese Urological Association","volume":"21","author":"Miki","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.purol.2022.09.009_bib0620","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5030349","article-title":"Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment","volume":"2019","author":"Dieckmann","year":"2019","journal-title":"BioMed Res Int"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0625","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00432-019-02844-z","article-title":"Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment","volume":"145","author":"Fankhauser","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib0630","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.euf.2016.11.018","article-title":"Longitudinal changes in serum levels of testosterone and luteinizing hormone in testicular cancer patients after orchiectomy alone or bleomycin, etoposide, and cisplatin","volume":"4","author":"Bandak","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib0635","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2016.07.029","article-title":"Serum Levels of MicroRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours","volume":"71","author":"Dieckmann","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.09.009_bib0640","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euros.2021.02.003","article-title":"Sequencing and miR-375 assay do not identify the presence of pure teratoma at postchemotherapy retroperitoneal lymph node dissection","volume":"26","author":"Lafin","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib0645","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2021.06.006","article-title":"Circulating MicroRNAs, the Next-generation serum biomarkers in testicular germ cell tumours: a systematic review","volume":"80","author":"Le\u00e3o","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib0650","first-page":"400","article-title":"Testicular tumors: what radiologists need to know--differential diagnosis, staging, and management","volume":"35","author":"Coursey Moreno","year":"2015","journal-title":"Radiogr Rev Publ Radiol Soc N Am Inc"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib0655","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000338771","article-title":"Testicular tumor ultrasound characteristics and association with histopathology","volume":"89","author":"McDonald","year":"2012","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib0660","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.juro.2017.08.004","article-title":"Prevalence and management of incidental small testicular masses discovered on ultrasonographic evaluation of male infertility","volume":"199","author":"Bieniek","year":"2018","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.purol.2022.09.009_bib0665","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/humrep\/dez083","article-title":"Clinical presentation, management and follow-up of 83 patients with Leydig cell tumors of the testis: a prospective case-cohort study","volume":"34","author":"Pozza","year":"2019","journal-title":"Hum Reprod Oxf Engl"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0670","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2214\/AJR.12.10319","article-title":"Testicular cancer: what the radiologist needs to know","volume":"200","author":"Kreydin","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0675","first-page":"1698","article-title":"Testicular germ cell tumors: classification, pathologic features, imaging findings, and management","volume":"41","author":"Katabathina","year":"2021","journal-title":"Radiogr Rev Publ Radiol Soc N Am Inc"},{"issue":"7","key":"10.1016\/j.purol.2022.09.009_bib0680","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1007\/s00330-015-4059-7","article-title":"Incidentally detected non-palpable testicular tumours in adults at scrotal ultrasound: impact of radiological findings on management Radiologic review and recommendations of the ESUR scrotal imaging subcommittee","volume":"26","author":"Rocher","year":"2016","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0685","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2214\/AJR.12.9064","article-title":"Dynamic contrast-enhanced subtraction MRI for characterizing intratesticular mass lesions","volume":"200","author":"Tsili","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0690","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/21681805.2020.1765863","article-title":"Multiparametric ultrasonographic analysis of testicular tumors: a single-center experience in a collective of 49 patients","volume":"54","author":"Schwarze","year":"2020","journal-title":"Scand J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0695","article-title":"Testicular microlithiasis in patients with testicular cancer in the United Kingdom and in Denmark","volume":"65","author":"Pedersen","year":"2018","journal-title":"Dan Med J"},{"key":"10.1016\/j.purol.2022.09.009_bib0700","doi-asserted-by":"crossref","first-page":"110000","DOI":"10.1016\/j.ejrad.2021.110000","article-title":"Ultrasonography of the scrotum: Revisiting a classic technique","volume":"145","author":"Tsili","year":"2021","journal-title":"Eur J Radiol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0705","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.eururo.2017.12.030","article-title":"Non-risk-adapted surveillance for Stage I Testicular Cancer: critical review and summary","volume":"73","author":"Pierorazio","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib0710","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.crad.2008.10.011","article-title":"Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours","volume":"64","author":"Sohaib","year":"2009","journal-title":"Clin Radiol"},{"issue":"11","key":"10.1016\/j.purol.2022.09.009_bib0715","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1442-2042.2009.02391.x","article-title":"Brain metastases from testicular germ cell tumors: a retrospective analysis","volume":"16","author":"Nonomura","year":"2009","journal-title":"Int J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.09.009_bib0720","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.eururo.2010.01.014","article-title":"Organ-sparing surgery for adult testicular tumours: a systematic review of the literature","volume":"57","author":"Giannarini","year":"2010","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0725","first-page":"1687","article-title":"Role of frozen section examination in the management of testicular nodules: a useful procedure to identify benign lesions","volume":"11","author":"Bozzini","year":"2014","journal-title":"Urol J"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0730","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.euf.2020.06.019","article-title":"The role of frozen section examination during inguinal exploration in men with inconclusive testicular tumors: a systematic review and meta-analysis","volume":"7","author":"Fankhauser","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.purol.2022.09.009_bib0735","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2022.03.013","article-title":"Metastatic potential of small testicular germ cell tumors: implications for surveillance of small testicular masses","volume":"40","author":"Pratsinis","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.purol.2022.09.009_bib0740","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15774","article-title":"Optimised detection of germ cell neoplasia in situ in contralateral biopsy reduces the risk of second testis cancer","author":"Rajpert-De Meyts","year":"2022","journal-title":"BJU Int"},{"issue":"4 Pt 2","key":"10.1016\/j.purol.2022.09.009_bib0745","article-title":"Testicular biopsy for early cancer detection--objectives, technique and controversies","volume":"34","author":"Dieckmann","year":"2011","journal-title":"Int J Androl"},{"key":"10.1016\/j.purol.2022.09.009_bib0750","first-page":"407","article-title":"Role of chemotherapy prior to orchiectomy in metastatic testicular cancer-is testis really a sanctuary site?","volume":"8","author":"Reddy","year":"2014","journal-title":"Ecancermedicalscience"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0755","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ucl.2019.04.006","article-title":"Management of primary testicular tumor","volume":"46","author":"Ghoreifi","year":"2019","journal-title":"Urol Clin North Am"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib0760","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/bju.12920","article-title":"Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy","volume":"117","author":"Robinson","year":"2016","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib0765","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.path.2018.07.005","article-title":"Updates in staging and reporting of testicular cancer","volume":"11","author":"Magers","year":"2018","journal-title":"Surg Pathol Clin"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0770","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/PAS.0000000000001049","article-title":"Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations","volume":"42","author":"Verrill","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.purol.2022.09.009_bib0775","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0780","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1097\/PAS.0000000000000844","article-title":"Reporting and staging of testicular germ cell tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations","volume":"41","author":"Verrill","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.purol.2022.09.009_bib0785","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"issue":"1","key":"10.1016\/j.purol.2022.09.009_bib0790","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cam4.324","article-title":"Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance","volume":"4","author":"Chung","year":"2015","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.purol.2022.09.009_bib0795","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2003.07.169","article-title":"Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial","volume":"21","author":"Albers","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib0800","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group","volume":"15","year":"1997","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.purol.2022.09.009_bib0805","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.20.03292","article-title":"Survival and new prognosticators in metastatic seminoma: results From the IGCCCG-Update Consortium","volume":"39","author":"Beyer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.purol.2022.09.009_bib0810","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium","volume":"39","author":"Gillessen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0815","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2164\/jandrol.112.016592","article-title":"The semen quality of 1158 men with testicular cancer at the time of cryopreservation: results of the French National CECOS Network","volume":"33","author":"Rives","year":"2012","journal-title":"J Androl"},{"issue":"30","key":"10.1016\/j.purol.2022.09.009_bib0820","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2012.43.4431","article-title":"Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up","volume":"30","author":"Haugnes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2016.11.015","article-title":"Sperm aneuploidy after testicular cancer treatment: data from a prospective multicenter study performed within the French Centre d\u2019\u00c9tude et de Conservation des Oeufs et du Sperme network","volume":"107","author":"Rives","year":"2017","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0830","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2021.08.025","article-title":"Expedited radical orchidectomy for testicular cancer: compromising fertility outcomes without oncological benefit?","volume":"80","author":"Emmanuel","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.09.009_bib0835","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2021.10.031","article-title":"Onco-Testicular Sperm Extraction (oncoTESE): A Contemporary Concept Review and Report of Australian Sperm Retrieval Rates and Fertility Outcomes","volume":"160","author":"Blecher","year":"2022","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0840","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/annonc\/mdi175","article-title":"Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review","volume":"16","author":"Hoei-Hansen","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0845","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/sj.bjc.6600771","article-title":"Radiotherapy with 16Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group","volume":"88","author":"Classen","year":"2003","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0850","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.critrevonc.2007.04.014","article-title":"A comprehensive systematic review of testicular germ cell tumor surveillance","volume":"64","author":"Groll","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0855","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2010.30.1044","article-title":"Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study Group","volume":"29","author":"Tandstad","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0860","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.eururo.2017.09.025","article-title":"Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel","volume":"73","author":"Boormans","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0865","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.eururo.2014.07.001","article-title":"A nationwide cohort study of stage I seminoma patients followed on a surveillance program","volume":"66","author":"Mortensen","year":"2014","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.purol.2022.09.009_bib0870","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1200\/JCO.2009.26.4655","article-title":"Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19\/EORTC 30982 study (ISRCTN27163214)","volume":"29","author":"Oliver","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0875","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.2005.08.003","article-title":"Randomized trial of 30 versus 20Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328)","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.purol.2022.09.009_bib0880","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/cncr.28086","article-title":"Outcomes in stage I testicular seminoma: a population-based study of 9193 patients","volume":"119","author":"Beard","year":"2013","journal-title":"Cancer"},{"issue":"34","key":"10.1016\/j.purol.2022.09.009_bib0885","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2013.53.5831","article-title":"Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort","volume":"32","author":"Daugaard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.09.009_bib0890","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.purol.2022.09.009_bib0895","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.2007.12.0899","volume":"26","author":"Albers","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.purol.2022.09.009_bib0900","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/annonc\/mdu375","article-title":"One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group","volume":"25","author":"Tandstad","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0905","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.eururo.2019.11.022","article-title":"The 111 Study: A Single-arm, Phase 3 Trial evaluating one cycle of bleomycin, etoposide, and cisplatin as adjuvant chemotherapy in high-risk, Stage 1 nonseminomatous or combined germ cell tumours of the testis","volume":"77","author":"Cullen","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.09.009_bib0910","doi-asserted-by":"crossref","first-page":"724682","DOI":"10.3389\/fonc.2021.724682","article-title":"Prophylaxis against thromboembolic events during chemotherapy for germ cell cancer","volume":"11","author":"Meng","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.09.009_bib0915","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.euf.2020.09.017","article-title":"A risk-benefit analysis of prophylactic anticoagulation for patients with metastatic germ cell tumours undergoing first-line chemotherapy","volume":"7","author":"Fankhauser","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.purol.2022.09.009_bib0920","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cam4.2674","article-title":"Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)","volume":"9","author":"Tran","year":"2020","journal-title":"Cancer Med"},{"issue":"3\u20134","key":"10.1016\/j.purol.2022.09.009_bib0925","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000512055","article-title":"Thromboembolic events in patients with testicular germ cell tumours are predominantly triggered by advanced disease and by central venous access systems","volume":"105","author":"Dieckmann","year":"2021","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib0930","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/JU.0000000000000366","article-title":"Treatment and outcome of patients with stage IS testicular cancer: a retrospective study from the Spanish germ cell cancer Group","volume":"202","author":"Aparicio","year":"2019","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0935","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","article-title":"Radiotherapy for stages IIA\/B testicular seminoma: final report of a prospective multicenter clinical trial","volume":"21","author":"Classen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib0940","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdu447","article-title":"Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes","volume":"26","author":"Giannatempo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.purol.2022.09.009_bib0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.04.031","article-title":"The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography","author":"Loriot","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0950","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000489408","article-title":"Clinical Stage IIA-IIC Seminoma: Radiation Therapy versus Systemic Chemotherapy versus Retroperitoneal Lymph Node Dissection","volume":"41","author":"von Amsberg","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib0955","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2013.09.004","article-title":"A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study","volume":"65","author":"Fizazi","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib0960","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/onco.13719","article-title":"Four cycles of etoposide plus cisplatin for patients with good-risk advanced germ cell tumors","volume":"26","author":"Funt","year":"2021","journal-title":"The Oncologist"},{"issue":"5","key":"10.1016\/j.purol.2022.09.009_bib0965","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdm062","article-title":"Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)","volume":"18","author":"Culine","year":"2007","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.purol.2022.09.009_bib0970","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1200\/JCO.2007.12.0808","article-title":"Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0975","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2004.07.178","article-title":"Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0980","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2005.05.4528","article-title":"Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.purol.2022.09.009_bib0985","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S1470-2045(14)70490-5","article-title":"Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.purol.2022.09.009_bib0990","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.ejca.2014.01.026","article-title":"Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours","volume":"50","author":"Thibault","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib0995","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ucl.2015.04.007","article-title":"The role of postchemotherapy surgery in germ cell tumors","volume":"42","author":"Ch\u00e9ry","year":"2015","journal-title":"Urol Clin North Am"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib1000","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2004.07.188","article-title":"2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial","volume":"22","author":"De Santis","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2022.09.009_bib1005","doi-asserted-by":"crossref","first-page":"852681","DOI":"10.1155\/2014\/852681","article-title":"Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis","volume":"2014","author":"Treglia","year":"2014","journal-title":"BioMed Res Int"},{"issue":"1","key":"10.1016\/j.purol.2022.09.009_bib1010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0022-5347(06)00508-8","article-title":"Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection","volume":"176","author":"Carver","year":"2006","journal-title":"J Urol"},{"issue":"36","key":"10.1016\/j.purol.2022.09.009_bib1015","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1200\/JCO.2008.17.1157","article-title":"[18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group","volume":"26","author":"Oechsle","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib1020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/JCO.2009.23.0714","article-title":"Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?","volume":"28","author":"Ehrlich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib1025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdw605","article-title":"Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours","volume":"28","author":"Heidenreich","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib1030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000489508","article-title":"Primary and postchemotherapy retroperitoneal lymphadenectomy for testicular cancer","volume":"41","author":"Heidenreich","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib1035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.euo.2019.08.002","article-title":"Surgical complications in postchemotherapy retroperitoneal lymph node dissection for nonseminoma germ cell tumour: a population-based study from the Swedish Norwegian Testicular Cancer Group","volume":"3","author":"Gerdtsson","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.09.009_bib1040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2008.09.027","article-title":"Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection","volume":"55","author":"Heidenreich","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib1045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euo.2021.02.002","article-title":"Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group","volume":"5","author":"Gerdtsson","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.purol.2022.09.009_bib1050","article-title":"Robotic postchemotherapy retroperitoneal lymph node dissection for testicular cancer","author":"Li","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib1055","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s11701-018-00903-0","article-title":"Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience","volume":"13","author":"Tamhankar","year":"2019","journal-title":"J Robot Surg"},{"issue":"5","key":"10.1016\/j.purol.2022.09.009_bib1060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.eururo.2019.05.031","article-title":"Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer","volume":"76","author":"Calaway","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib1065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00345-009-0412-2","article-title":"Management of post-chemotherapy extra-retroperitoneal residual masses","volume":"27","author":"Carver","year":"2009","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.09.009_bib1070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.urology.2011.09.038","article-title":"Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer","volume":"79","author":"Masterson","year":"2012","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib1075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ucl.2015.04.011","article-title":"Role of extraretroperitoneal surgery in patients with metastatic germ cell tumors","volume":"42","author":"Hu","year":"2015","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.purol.2022.09.009_bib1080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.urology.2018.01.014","article-title":"Clinical outcome of retroperitoneal lymph node dissection after chemotherapy in patients with pure embryonal carcinoma in the orchiectomy specimen","volume":"114","author":"Dowling","year":"2018","journal-title":"Urology"},{"issue":"33","key":"10.1016\/j.purol.2022.09.009_bib1085","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","article-title":"Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy","volume":"28","author":"Lorch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.09.009_bib1090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/0284186X.2011.641507","article-title":"High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA)","volume":"51","author":"Haugnes","year":"2012","journal-title":"Acta Oncol Stockh Swed"},{"issue":"16","key":"10.1016\/j.purol.2022.09.009_bib1095","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","article-title":"Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: Evidence from a large international database","volume":"29","author":"Lorch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.09.009_bib1100","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/annonc\/mdu099","article-title":"Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial","volume":"25","author":"Fizazi","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.09.009_bib1105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ucl.2015.04.010","article-title":"Late relapse of testicular germ cell tumors","volume":"42","author":"O'Shaughnessy","year":"2015","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.purol.2022.09.009_bib1110","article-title":"Management of late relapses after chemotherapy in testicular cancer: optimal outcomes with dose-intense salvage chemotherapy and surgery","author":"Alifrangis","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.purol.2022.09.009_bib1115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051127","article-title":"Very late recurrence in germ cell tumor of the testis: lessons and implications","volume":"14","author":"Moore","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.purol.2022.09.009_bib1120","first-page":"416","article-title":"sous-comit\u00e9 OGE du comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie. [Testicular germ cell tumors late relapses]","volume":"20","author":"Durand","year":"2010","journal-title":"Progres En Urol J Assoc Francaise Urol Soc Fr Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.09.009_bib1125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.20.02352","article-title":"Dose-dependent effect of platinum-based chemotherapy on the risk of metachronous contralateral testicular cancer","volume":"39","author":"Blok","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.purol.2022.09.009_bib1130","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2006.08.4889","volume":"25","author":"Rustin","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722004006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722004006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:36:00Z","timestamp":1761114960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708722004006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":113,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1166708722004006"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2022.09.009","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2022.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}